About this trial
The primary objective of this study is to identify the molecular identity profiles of all cellular states that characterize the progression from benign nevi to malignant melanoma in CAYA patients with L/GCMN. The secondary objectives are:
* To longitudinally characterize the cell-free DNA (cfDNA) from CAYA patients. * To improve the early diagnosis and treatments for intermediate conditions such as L/GCMN through evidence-based interpretation of personal risk from endogenous or exogenous sources. * To test pre-clinical strategies to best model and improve patient response.
Eligibility criteria
Qualifiers
Congenital nevus with estimated size of 20 cm
Be over 18 years of age
Disqualifiers
No available biological material
Not having signed the informed consent
Trial design
Treatments tested in this trial
- Methylomics
- RNA sequencing
- Spatial transcriptomics
- Liquid biopsy
Treatment groups
Sponsors and collaborators
Fundacion Clinic per a la Recerca Biomédica
Lead sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Collaborator
University Hospital Tuebingen
Collaborator
University of Florence
Collaborator
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Collaborator
University Of Perugia
Collaborator
German Cancer Research Center
Collaborator
Karolinska Institutet
Collaborator
Maria Sklodowska-Curie National Research Institute of Oncology
Collaborator
Institut Curie
Collaborator
Medical University of Gdansk
Collaborator
Princess Maxima Center for Pediatric Oncology
Collaborator
Institut Català d'Oncologia
Collaborator